Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients

https://doi.org/10.1016/0192-0561(86)90067-6Get rights and content

Abstract

The pharmacokinetics of azathioprine (AZA) and 6-mercaptopurine (6-MP) was studied in uremic patients after 100 mg AZA intravenously (fifteen patients) and orally (eight patients). 6-MP was analysed with gas chromatography mass spectrometry following extractive alkylation. AZA was determined indirectly assuming quantitative conversion to 6-MP in whole blood. The plasma concentration of AZA fell rapidly after i.v. administration. The mean half-time of elimination for the first rapid phase (t12α was 6.1 min (S.D. ± 4.1) and for the terminal phase (t12β) 50 min (± 31). The total plasma clearance (C1) was 6.91./min (± 3.0). AZA was rapidly converted to 6-MP in vitro, and maximal plasma concentrations of 6-MP were found as early as 5 min after i.v. injection of AZA. The mean t12α was 4.6 min (± 2.2), t12β 74 min (± 58) and C1 8.01/min (± 5.8). The plasma levels of both AZA and 6-MP were either low or undetectable 4–6 h after dose. In erythrocytes AZA levels were low or undetectable indicating rapid conversion to 6-MP in these cells. 6-MP concentration - time curve in erythrocytes was similar to that in plasma, except for a somewhat slower terminal phase of elimination. Oral administration of AZA generated flat plasma curves for AZA and 6-MP. The area under the concentration - time curve (AUC) was considerably smaller than after i.v. administration, 18 and 41% for AZA and 6-MP, respectively. There seems to be little danger of accumulation of AZA/6-MP in uremia. We also studied inhibition of Leucoagglutin (LA) stimulated lymphocyte proliferation by patient plasma at different times in six of the patients following AZA i.v. Sera drawn at 5, 10 and 30 min significantly inhibited the LA-induced proliferation, with an estimated minimum effective concentration of 6-MP in the cultures of about 0.02–0.04 μM. This suggests the possibility of a therapeutic effect even of the low plasma levels of 6-MP obtained after AZA orally. The combined use of sensitive pharmacokinetic and immunological assays as described should be useful in studying the relationship between plasma levels of AZA/6-MP and their immunosuppressive effect and toxicity.

References (29)

  • M.C. Berebaum

    Is azathioprine a better immunosuppressive than 6-mercaptopurine?

    Clin. exp. Immun.

    (1971)
  • R.Y. Calne

    Renal Transplantation

    (1967)
  • R.Y. Calne et al.

    A study of the effects of drugs in prolonging survival of homologous renal transplants in dogs

    Ann. N.Y. Acad. Sci.

    (1962)
  • A.H. Chalmers et al.

    6-thiopurines as substrates and inhibitors of purine oxidase: a pathway for conversion of azathioprine into 6-thiouric acid without release of 6-mercaptopurine

    Aust. J. exp. Biol. med. Sci.

    (1969)
  • Cited by (39)

    • The impact of glutathione S-transferase genotype and phenotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases

      2015, Journal of Pharmacological Sciences
      Citation Excerpt :

      After oral application of AZA, very little it is detectable in patient plasma (26–28). Similar observations have been reported in mice (29) and the rhesus monkey (30). It was that indicated erythrocytes play a major role in this step in vivo.

    • Glutathione transferases in the bioactivation of azathioprine

      2014, Advances in Cancer Research
      Citation Excerpt :

      The steady-state kinetic parameters were determined and were similar for all except A2*E, which had three- to fourfold higher kcat and kcat/KM values (Zhang et al., 2010). Assuming in vivo azathioprine concentrations < 10 μM (Odlind et al., 1986) and KM values > 1 mM, the data indicated that the activation rate under physiological conditions is proportional to kcat/KM. Variant A2*E turned out to catalyze this reaction three- to fourfold faster than the other variants of A2-2 and about sixfold faster than GSTs A1-1 and M1-1.

    View all citing articles on Scopus
    View full text